Heba Samy Shoukry
Background: Depression is of high prevalence among rheumatoid arthritis patients compromising the physical and psychological aspects of quality of life. It is highly associated with VIT D level.
Patients and methods: This study included 200 RA patients. (BDI) was used to detect depression. Disease activity was measured using disease activity score (DAS-28) and Rheumatoid Arthritis Disease Activity Index (RADAI-5). The Modified Health Assessment Questionnaire (MHAQ) was used for measuring disability. Rheumatoid Arthritis Quality of Life scale (RAQoL), Visual Analogue Score-pain (VAS-pain), and Fatigue Severity Scale (FSS) scores were calculated.
Results: The mean disease duration 6.75 ± 4.32 years, 69.5% were females and 30.5% males (F: M 2.27:1). Their mean DAS-28 was 3.97 ± 1.19 and MHAQ 1.27 ± 0.63. The mean BDI II score was 21 ± 12.61. 48.5% of the patients had moderate depression 4.5% had severe depression. BDI II significantly correlated with erythrocyte sedimentation rate, C-reactive protein, DAS-28, MHAQ, RAQoL VAS-pain FSS and RADAI (p=0.001).
Conclusion: Depression is highly prevalent among rheumatoid arthritis patients. Screening for depression periodically in RA should be included management protocols to avoid poor outcomes.
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi